AelisFarma

Aelis Farma ‘s
Phase I clinical trial initiated in January 2017

AelisFarma

Aelis Farma specializes in the development of first-in-class CB1 Signaling Specific inhibitors.

Our first therapeutic target is cannabis abuse. Since the CB1 receptor is involved in a large number of diseases, other potential therapeutic applications for the company’s compounds are potentially numerous, including psychosis, mental retardation, metabolic disorders and skin diseases.

Aelis Farma is a pioneer  in the development of signaling specific therapeutics that target GPCRs (and more specifically the CB1 receptor which is one of the most expressed GPCRs in the brain). GPCRs are the target of most therapeutic drugs. This family of receptors has the characteristics to activate several and often opposing signaling pathways. Unfortunately, most of the drugs acting on GPCRs either block or stimulate the entire signaling activity of the receptor resulting in unwanted and sometimes unacceptable side effects.

The signaling specific drugs of Aelis Farma, mimicking physiology, offer the promise of a new frontier in drug design and development: such drugs will selectively modulate only the signaling pathway involved in the disease, thus providing a new class of pharmaceutical compounds with higher therapeutic efficacy and fewer side effects.

 

 

 

Aelis Farma ‘s
Phase I clinical trial initiated in January 2017

AelisFarma